This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus Therapeutics' CEO John F. Crowley To Advocate For Rare And Orphan Disease Community In Washington, D.C. This Week

Speaking at Research!America National Health Research Forum with FDA Commissioner Hamburg

Moderating Panel Discussion on Capitol Hill at Rare Disease Congressional Caucus Briefing

Joining Rep. Leonard Lance and Rep. Joe Crowley to Reintroduce "MODDERN CURES ACT"

CRANBURY, N.J., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will advocate for the rare and orphan disease community at several upcoming events in Washington, D.C tomorrow on September 12, 2013:

Rare Disease Congressional Caucus Briefing

Date: Thursday, September 12, 2013

Time: 10:00 a.m. ET

Place: Rayburn House Building

Mr. Crowley will moderate a panel discussion at a briefing of the Congressional Rare Disease Caucus entitled, "In Jeopardy: Programs that Accelerate the Development of Rare Disease Treatments." The Rare Disease Congressional Caucus, co-chaired by Representatives Leonard Lance (R-NJ) and Joe Crowley (D-NY), is a forum for members of Congress to voice constituent concerns, share ideas, and build support for legislation that will improve the lives of people with rare diseases. During the hearing, Mr. Crowley and the panelists will discuss:
  • The timely implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) in giving people with rare diseases access to Accelerated Approval
  • Regulatory challenges that prevent access for U.S. patients to participate in clinical trials for rare disease treatments in development
  • The potential elimination of the Orphan Drug Tax Credit
  • The Food and Drug Administration Safety Over Sequestration Act of 2013, H.R. 2725

In conjunction with the Caucus Briefing, Mr. Crowley will join Representatives Lance and Crowley to support the reintroduction of the bipartisan "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network (MODDERN) Cures Act."

"We are fortunate to have the support of John Crowley, a nationally recognized rare disease advocate, as we reintroduce The MODDERN Cures Act," stated Congressman Lance. "This legislation seeks to promote the development of meaningful cures for the rarest diseases that have few or no options by removing outdated barriers and creating new invention and innovation opportunities." 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,630.27 +189.68 1.09%
S&P 500 2,093.25 +25.61 1.24%
NASDAQ 5,089.2060 +49.43 0.98%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs